Regional Infusion of a Class C TLR9 Agonist Enhances Liver Tumor Microenvironment Reprogramming and MDSC Reduction to Improve Responsiveness to Systemic Checkpoint Inhibition

Comparison of pancreatic tissue uptake of oxaliplatin delivered by systemic circulation and by pancreatic retrograde venous infusion (PRVI)

Abstract No. 158628: PERIO-01: Enabling Tumor Microenvironment Reprogramming by a TLR9 Agonist Using Pressure-Enabled Drug Delivery™ (PEDD™) to Address Intrahepatic Immunosuppression and Drug Delivery Barriers

Antireflux Catheter Improves Tumor Targeting in Liver Radioembolization with Resin Microspheres

Abstract No. 1793: Regional Administration of Class C CpG Oligodeoxynucleotides Results in Superior Intrahepatic TLR9 Activation and Immunomodulation Compared to Systemic Infusion

HITM-SURE: Hepatic Immunotherapy for Metastases Phase Ib Anti-CEA CAR-T Study Utilizing Pressure Enabled Drug Delivery

Abstract No. 9534: Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)

Abstract No. 9555: Phase 1b/2, Open Label, Multicenter Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced/Metastatic Melanoma Resistant to Anti-PD-1/PD-L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)

Abstract 6039: Phase 1b/2, Open Label, Multicenter Study of Intratumoral SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001/KEYNOTE-184, NCT02521870)

STAT3 Inhibition Induces Bax-dependent Apoptosis in Liver Tumor Myeloid-Derived Suppressor Cells
